Fig. 1

Fig. 2

Prevalent characterization of Beijing and non-Beijing family strains_
| Characteristics | Beijing family | Non-Beijing family | ||||||
|---|---|---|---|---|---|---|---|---|
| Clustered n = 612 | Non-clustered n = 508 | OR (95% CI) | p-value | Clustered n = 46 | Non-clustered n = 267 | OR (95% CI) | p-value | |
| Sex | ||||||||
| Men | 384 | 267 | – | – | 32 | 177 | – | – |
| Women | 228 | 241 | 1.210.–512. 93 | 0 .001 | 14 | 90 | 0.519.–126. 29 | 0.74 |
| Age | ||||||||
| ≤ 30 | 187 | 176 | – | – | 13 | 78 | – | – |
| 30–50 | 232 | 149 | 0.501.–608. 91 | 0 .01 | 19 | 67 | 0.207.5–818.2 8 | 0.24 |
| ≥ 50 | 193 | 183 | 0.716.–011. 34 | 1 .00 | 14 | 122 | 0.615.–435. 25 | 0.41 |
| Treatment history | ||||||||
| New | 530 | 461 | – | – | 32 | 203 | – | – |
| Recurrent | 67 | 38 | 0.403.–605. 99 | 0 .05 | 11 | 52 | 0.305.–714. 58 | 0.42 |
| Treatment failure | 15 | 9 | 0.300.–619. 59 | 0 .42 | 3 | 14 | 0.200.–724. 70 | 0.71 |
| HIV status | ||||||||
| Positive | 28 | 23 | – | – | 2 | 14 | – | – |
| Negative | 584 | 485 | 0.518.–011. 78 | 1 .00 | 44 | 253 | 0.108.–832. 74 | 1.00 |
| Sputum | ||||||||
| Negative | 121 | 104 | – | – | 12 | 83 | – | – |
| Positive | 391 | 404 | 0.819.–210. 62 | 0 .23 | 34 | 184 | 0.309.–718. 59 | 0.60 |
| Cavity | ||||||||
| No | 494 | 432 | – | – | 39 | 225 | – | – |
| Yes | 118 | 76 | 0.919.–316. 86 | 0 .07 | 7 | 42 | 0.400.–926. 30 | 1.00 |
Demographic and drug-resistant characteristics of this study’s isolates (n = 1,433)_
| Characteristics | Number | Beijing family | Non-Beijing family | OR (95% CI) | p-value |
|---|---|---|---|---|---|
| All | 1,433 | 1,120 | 313 | – | – |
| Sex | |||||
| Men | 860 | 651 | 209 | – | – |
| Women | 57 3 | 41 9 | 154 | 0.910.–114. 46 | 0.29 |
| Age | |||||
| ≥ 50 | 512 | 376 | 136 | – | – |
| 30–50 | 46 7 | 38 1 | 86 | 1.114.–414. 83 | 0.003 |
| ≤ 30 | 45 4 | 36 3 | 91 | 1.015.–313. 67 | 0.02 |
| Treatment history | |||||
| New | 1,174 | 900 | 274 | – | – |
| Recurrent | 16 8 | 14 5 | 23 | 0.303.–502. 83 | 0.004 |
| Treatment failure | 91 | 7 5 | 16 | 0.400.–710. 22 | 0.24 |
| Region | |||||
| Southern regions | 249 | 181 | 68 | – | – |
| Central regions | 72 2 | 56 7 | 155 | 0.502.–713. 01 | 0.07 |
| Northern regions | 46 2 | 37 2 | 90 | 0.405.–604. 92 | 0.02 |
| DST profile | |||||
| DST profile | 1,433 | 1,120 | 313 | – | – |
| Pansusceptible | 99 2 | 79 4 | 198 | 0.703.–819. 09 | 0.27 |
| RIF | 2 7 | 1 8 | 9 | 0.810.–749. 02 | 0.16 |
| INH | 3 3 | 2 5 | 8 | 0.511.–124. 56 | 0.68 |
| SM | 5 2 | 4 4 | 8 | 0.300.–615. 40 | 0.31 |
| EMB | 6 | 5 | 1 | 0.008.–762. 15 | 1.00 |
| AK | 1 9 | 1 5 | 4 | 0.301.–925. 90 | 1.00 |
| CM | 1 8 | 1 3 | 5 | 0.419.–338. 89 | 0.57 |
| LEV | 3 8 | 3 0 | 8 | 0.403.–925. 10 | 1.00 |
| RIF + INH | 5 6 | 4 7 | 9 | 0.303.–618. 41 | 0.41 |
| RIF + SM | 2 0 | 1 5 | 5 | 0.413.–139. 31 | 0.78 |
| INH + SM | 4 1 | 3 4 | 7 | 0.302.–714. 68 | 0.57 |
| RIF + EMB | 5 | 3 | 2 | 0.402–.3194 .34 | 0.30 |
| INH + EMB | 1 | 1 | 0 | – | – |
| RIF + INH + EMB | 7 1 | 6 0 | 11 | 0.304.–616. 26 | 0.24 |
| RIF + INH + SM | 2 9 | 2 5 | 4 | 0.200.–517. 66 | 0.37 |
| INH + SM + EMB | 5 | 4 | 1 | 0.100.–980. 03 | 1.00 |
| RIF + INH + SM + EMB | 2 | 1 | 1 | 0.223–.5587 .37 | 0.39 |
| MDR | 158 | 133 | 25 | 0.410.64 –1.01 | 0.05 |
Prevalent characterization of clustered and non-clustered strains_
| Characteristics | Clustered | Non-clustered | ||||||
|---|---|---|---|---|---|---|---|---|
| Beijing family n = 612 | Non-Beijing family n = 46 | OR (95%CI) | p-value | Beijing family n = 508 | Non-Beijing family n = 267 | OR (95%CI) | p-value | |
| Sex | ||||||||
| Men | 384 | 32 | – | – | 267 | 177 | – | – |
| Women | 228 | 14 | 0.308.–714. 41 | 0.43 | 241 | 90 | 0.401.–506. 77 | < 0.001 |
| Age | ||||||||
| ≤ 30 | 187 | 13 | – | – | 176 | 78 | – | – |
| 30–50 | 232 | 19 | 0.517.–128. 45 | 0.72 | 149 | 67 | 0.618.–012. 50 | 1.00 |
| ≥ 50 | 193 | 14 | 0.418.–024. 28 | 1.00 | 183 | 122 | 1.016.5–024.1 4 | 0.03 |
| Treatment history | ||||||||
| New | 507 | 28 | – | – | 443 | 246 | – | – |
| Recurrent | 84 | 14 | 1.533.–052. 97 | 0.003 | 61 | 9 | 0.103.2–606.5 4 | 0.00 |
| Treatment failure | 21 | 4 | 1.131.–41409. 73 | 0.05 | 4 | 12 | 1.752.–41062. 93 | 0.002 |
| HIV status | ||||||||
| Negative | 584 | 37 | – | – | 485 | 260 | – | – |
| Positive | 28 | 9 | 0.009.–200. 45 | 0.001 | 23 | 7 | 0.715.–746. 16 | 0.24 |
| Sputum | ||||||||
| Negative | 121 | 12 | – | – | 104 | 83 | – | – |
| Positive | 391 | 34 | 0.440.88 –1.75 | 0.72 | 404 | 184 | 0.410.57 –0.80 | 0.001 |
| Cavity | ||||||||
| Yes | 108 | 7 | – | – | 86 | 42 | – | – |
| No | 504 | 39 | 0.512.–129. 74 | 0.84 | 422 | 225 | 0.713.–019. 63 | 0.76 |